Incorporating Precision Medicine Into the Treatment of NSCLC
Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.
Edward Kim, MD, FACP, of the Levine Cancer Institute, Carolinas Healthcare System in Charlotte, North Carolina, offers insight into the changing treatment paradigms in non-small lung cancer, and why many patients can now have indivdualized therapy plans based on the genetic make-up of their disease and the advances in the field.
We spoke with Dr. Kim at the 2017 ASCO annual meeting, where he presented at an education session entitled, "Incorporating Precision Medicine Into Your Practice: How, Why, and When?"
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
